This site is intended for healthcare professionals
News

Phase III IPATential150 study with RG 7440 plus Zytiga meets co-primary endpoint in prostate cancer.- Genentech/Roche

Read time: 1 mins
Last updated:23th Jun 2020
Published:20th Jun 2020
Condition: Prostate Cancer
Type: drug
Register free for full access to medthority.com